Evidence Level
Noopept was developed at the Russian Academy of Medical Sciences and has been extensively studied in Russian clinical literature. Ostrovskaya et al. (2008) demonstrated that chronic administration of Noopept increases brain-derived neurotrophic factor (BDNF) expression in the rat hippocampus, suggesting potential neuroprotective effects against Alzheimer's disease. Additionally, Gudasheva et al. (1997) established its high potency, with Noopept being 1000 times more potent than piracetam by weight. The study revealed that Noopept acts as a prodrug, converting into cyclo-L-prolylglycine in the rat brain, which increases its concentration 2.5-fold compared to piracetam.
Russian clinical trials have shown cognitive benefits of Noopept in patients with mild cognitive impairment and post-stroke cognitive deficits. Ostrovskaya et al. (2014) further explored its neuroprotective effects, highlighting its potential role in mitigating Alzheimer's disease-related mechanisms both in vitro and in vivo. However, Western clinical trials remain limited, with most evidence derived from preclinical models and Russian studies.